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Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, IsraelShould FibroTest and/or Fibroscan replace liver biopsies in the
follow-up of patients treated with low-dose methotrexate?
Low-dose methotrexate (MTx, 2.5–25 mg/week) has been used
successfully for several decades in the treatment of non-malig-
nant diseases such as psoriasis (Ps), rheumatoid arthritis (RA)
[1–4], as well as Crohn’s disease (CrD). High-dose administration
of MTx (at 100–1000 mg/mm2) for various malignancies may
lead to stomatitis, gastrointestinal, hepatic, and pulmonary toxic-
ity as well as bone-marrow suppression. In contrast, low-dose
MTx is less toxic and the main undesired effect is hepatotoxicity.
Soon after the introduction of MTx for long-term, low-dose treat-
ment regimens, it became clear that aminotransferase and alka-
line phosphatase elevations are relatively frequent and often
reversible. Conﬂicting data have been reported regarding the
incidence of MTx-associated hepatotoxicity. In one report, 22%
of MTx recipients with RA and twice as much with Ps arthritis
had evidence for abnormal liver functions [1]. Cirrhosis was
reported in 25% of patients with Ps arthritis receiving long-term
low-dose MTX [2] and in <2% of patients with RA [3] This differ-
ence in the hepatoxic potential of MTx between patients with Ps
and RA was not conﬁrmed in a recent study [5]. MTx may lead to
a spectrum of hepatic histologic abnormalities including steato-
sis, hypertrophy of stellate cells, variations in hepatocyte nuclei
size, as well as ﬁbrosis which are not always associated with
elevated AST or ALT. Until recently, it was believed that MTx-
induced hepatotoxicity was dose dependent and guidelines
recommended performing a liver biopsy after every 1.0–1.5 g of
cumulative MTx intake. Nowadays, it seems that hepatotoxicity
is not necessarily MTx dose dependent and may be associated
with a number of risk factors including a history of more than
moderate alcohol intake, diabetes mellitus, obesity, hyperlipid-
emia, presence of underlying liver disease, female gender, and
inadequate supplementation with folate. Consequently, recent
guidelines have limited the use of liver biopsies in the monitoring
of Ps patients without such risk factors [4]. Hepatologists are fre-
quently confronted with questions regarding the safety of contin-
uous administration of MTx in patients with Ps, RA, or CrD
disease. The introduction of new non-invasive tests such as Fibro-
Test and FibroScan for the assessment of hepatic inﬂammatory
activity and ﬁbrosis is now being explored in a variety of liver
diseases as a means for replacing liver biopsies in the diagnosis
and monitoring of occult and overt liver injury. Pilot studiesJournal of Hepatology 20
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already provided some preliminary evidence that FibroTest pre-
dicts the presence of ﬁbrosis, whereas FibroScan, the absence of
ﬁbrosis in MTx-treated patients [6,7].
In this issue of the Journal, Laharie and co-workers [8] have
expanded their initial observation using FibroTest and FibroScan
in 384 MTx-treated patients and 128 case controls (124, 149, and
111 patients with CrD, RA, and PS, respectively). An additional
group of 134 patients, with other inﬂammatory diseases treated
by MTx, were also evaluated by the same methodology. The main
ﬁndings of this large prospective study revealed that only an
overall 8.5% of MTx recipients had indirect evidence by FibroTest
(0.58 cut off) and/or FibroScan (7.9 kPa cut off) for severe ﬁbrosis.
Interestingly, and conﬁrming earlier small-scale observations,
multivariate analysis revealed that neither cumulative dose nor
treatment duration of MTx was associated with signiﬁcant ﬁbro-
sis. On the other hand, risk factors such as an increased intake of
alcohol and body mass index >28 kg/m2 were associated with a
higher rate of ﬁbrosis as determined by these non-invasive proce-
dures. Furthermore, of the 43 patients with evidence for severe
liver ﬁbrosis based on either of these tests, advanced ﬁbrosis
was detected by both non-invasive tests in only 7/43 patients,
while 24/43 were positive by FibroScan alone and 12 by FibroTest
alone. The discrepancy between the results obtained by the dif-
ferent non-invasive methods does not enable to distinguish
which of the two tests is superior for monitoring MTx recipients.
Further exploration is required to form an opinion whether both
FibroTest and FibroScan or only one of these tests will be enough
for follow-ups. Nevertheless, these data provide an important
contribution in addressing the controversy surrounding the rele-
vance and timing for the indication of a liver biopsy and support
the introduction of such technique(s) in the follow-up of low-
dose MTx recipients (especially in Ps). One should, however, keep
in mind that the study had some limitations including the rela-
tively short follow-up time of MTx recipients, the relatively low
cumulative median dose of MTx administered, the small number
of patients with ﬁbrosis who underwent a liver biopsy, and the
disparities between the results of FibroScan and FibroTest. Based
on the results of this study, it seems at present premature to rec-
ommend an overall transition from cumulative MTx-driven liver
biopsies to the non-invasive follow-up of patients with FibroScan
and or FibroTest. Yet, the future looks promising regarding the
role of such tests in the follow-up of patients at risk. Decisions
regarding the performance of a liver biopsy during the follow-
up of MTx recipients should be individualized based on the clin-
ical evidence of advanced ﬁbrosis by non-invasive techniques,10 vol. 53 j 987–989
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and/or suspicion for an underlying liver disease or risk factor not
related to MTX intake. A longer follow-up of the patients included
in this study is required. The good news is that the rates of
advanced ﬁbrosis and cirrhosis in this large cohort of MTx recip-
ients seem to be lower than those previously reported.Fading expectations regarding the beneﬁcial effect of N-
acetylcystein in the treatment of severe alcoholic hepatitis
Severe acute alcoholic hepatitis is associated with a 40–50% mor-
tality within 8 weeks in hospitalized patients with a discrimi-
nant function (DF) P32 and/or hepatic encephalopathy. Several
therapeutic interventions have been evaluated so far in an
attempt to control the devastating alcohol-induced hepatic injury
and its consequences. These include administration of corticoste-
roids, pentoxifylline, anti-TNF agents, oxandrolone, silymarine,
nutritional and general support measures, and anti-oxidants
[9,10]. Treatment with corticosteroids in a subgroup of non-
bleeding, non-septic patients remains so far the most effective
therapeutic intervention to improve the short-term (one month)
survival in such patients [11]. In one study, the administration of
pentoxifylline was shown to improve the 28 day mortality rate by
almost 50% in a small placebo controlled trial and reduced the
development of hepatorenal syndrome [12]. Except for these
two modalities, none of the other above-mentioned measures
has been shown to provide signiﬁcant survival beneﬁts in such
patients. Yet, treatment with anti-oxidants for alcoholic hepatitis
continues to attract the attention of investigators in the ﬁeld
despite repeated failures recorded in clinical trials using, among
others, vitamins E, biotin, desferrioxamine, selenium, zinc, man-
ganese, copper, and magnesium [13,14]. The continued interest
in the potential value of anti-oxidants in the treatment of alco-
holic hepatitis is driven by ample evidence obtained in experi-
mental models as well as in humans, implicating oxidative
stress as an important mechanism involved in hepatic injury.
Hence, blocking pro-oxidant reactive oxygen species (ROS) and,
as a consequence, slowing down lipid peroxidation and mito-
chondrial injury remain an important goal.
N-Acetylcystein (NAC) is a potent anti-oxidant with an estab-
lished record as an antidote in paracetamol over-dose. NAC, a
glutathione precursor, replenishes hepatic glutathione and sup-
presses ROS. The evidence regarding the efﬁcacy of NAC in ful-
minant hepatitis, not related to paracetamol over-dose, is
rather limited. However, NAC is by now frequently used as part
of intensive care in patients with acute liver failure (ALF), irre-
spective of the etiology. Support for the use of NAC in ALF was
recently obtained by the US Acute Liver Failure Study Group
who conducted a double blind, randomized controlled trial using
intravenous (IV) NAC or placebo for 72 h in 173 ALF patients
(non-acetaminophen ALF of whom 45 were related to drug
injury) [15]. IV NAC did not improve the short-term 3 week
survival but signiﬁcantly improved the transplant-free survival
in 40% vs 27% of NAC and placebo recipients, respectively
(p = 0.043). It was, therefore, expected that NAC treatment would
also be evaluated in alcoholic hepatitis. An early study performed
in 70 patients with alcoholic hepatitis, all of whom were treated
by corticosteroids, compared 1 week of NAC treatment followed
by the intake of a cocktail of anti-oxidants with placebo for
6 months [14]. In this study, anti-oxidant treatment with or988 Journal of Hepatology 201without corticosteroids did not provide a survival beneﬁt by
6 months.
In the present issue of the Journal, Moreno and co-workers
evaluated, in a single blinded study, the 1 and 6 months survival
rates in 52 patients receiving entral nutrition with or without IV
NAC at 300 mg/kg for 14 days [16]. The study design differed
from the study of Stewart et al. [14] and included a longer intake
of NAC and the absence of corticosteroid treatment. No statisti-
cally signiﬁcant difference at 1 and 6 months could be demon-
strated between the study groups after recruiting the ﬁrst 52
patients. An interim analysis performed at that stage concluded
that in order to reach the study goals and a deﬁnite conclusion
at a power of 80%, the study population should be expanded to
1022 patients. As a result, the study was discontinued and the
value of NAC in the treatment of alcoholic hepatitis remains
questionable at best. Based on the information obtained in the
study of Stewart et al. and the present and incomplete study by
Moreno et al., there still is no proof for a beneﬁcial effect on sur-
vival of anti-oxidant therapies in general and of NAC in particular.
This impression is also reﬂected in the recent guidelines on alco-
holic liver disease of the American Association for the Study of
the Liver which do not support the inclusion of NAC in the treat-
ment of severe alcoholic hepatitis [17]. It remains to be seen if
this new report will be the last nail in the cofﬁn of anti-oxidant
therapy in alcoholic hepatitis.Conﬂicts of interests
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